Tag Archives: nivolumab

Study to Test Nivolumab and Chemotherapy for Mesothelioma

Nivolumab and Chemotherapy

Researchers in Germany are recruiting patients for a trial of nivolumab and chemotherapy for pleural mesothelioma patients who have had surgery. Nivolumab (Opdivo) is an immunotherapy drug similar to pembrolizumab (Keytruda). It blocks a protein that helps mesothelioma cells hide from the immune system. Nivolumab is most often used for patients with non-small cell lung cancer. The multicenter German study will test if a combination of nivolumab and chemotherapy can help keep tumors from growing back after mesothelioma surgery. Previous studies suggest that it has the potential to do so. How Immune Checkpoint Inhibitors Work Immune checkpoint inhibitors like nivolumab, pembrolizumab, and ipilimumab (Yervoy) are a major focus for mesothelioma researchers. Mesothelioma cells are notoriously tenacious. They often fail to … Continue reading Study to Test Nivolumab and Chemotherapy for Mesothelioma »

New Drug Combination for Mesothelioma Wins FDA Approval

New Drug Combination for Mesothelioma

The FDA has approved a new drug combination for mesothelioma. It is the first systemic treatment for mesothelioma to win FDA approval in 16 years.  The combination includes a pair of immunotherapy drugs that complement each other. Both drugs are immune checkpoint inhibitors. They are approved to treat people with inoperable pleural mesothelioma.  “Today’s approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma,” says Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence. New Treatment Options Needed Pleural mesothelioma is a virulent cancer of the membrane that surrounds the lungs. Asbestos exposure is usually the trigger. Many countries have banned asbestos. In the US, … Continue reading New Drug Combination for Mesothelioma Wins FDA Approval »

“Exceptional Survival” in Some Patients on Nivolumab for Mesothelioma

nivolumab for mesothelioma

A real-world study of Dutch patients suggests that nivolumab for mesothelioma can dramatically extend survival in the right patients.  Nivolumab is sold under the brand name Opdivo. It is a type of immunotherapy. It works by making cancer cells more vulnerable to attack. The FDA approved nivolumab to treat non-small cell lung cancer and some other cancers.  It is still in the testing phase for malignant mesothelioma. The new report suggests that careful patient selection is the key to making nivolumab for mesothelioma work.  Why Nivolumab for Mesothelioma? Malignant mesothelioma is an aggressive cancer caused by past exposure to asbestos. Like other types of cancer, it has ways of protecting itself from immune system attack. A protein called PD-L1 is … Continue reading “Exceptional Survival” in Some Patients on Nivolumab for Mesothelioma »

Opdivo for Mesothelioma Recurrence is Safe and Effective, Study Finds

Opdivo for mesothelioma recurrence

A new Japanese study appears to show that Opdivo for mesothelioma recurrence after surgery is safe and effective.  Opdivo (nivolumab) is an immunotherapy drug similar to Keytruda (pembrolizumab). It blocks a protein called PD-L1. PD-L1 helps mesothelioma cells avoid detection by the immune system.  In the latest study, 35 patients received Opdivo for mesothelioma recurrence. More than three quarters of them experienced either stable or decreased disease. Understanding How Nivolumab Works Nivolumab is most often used to treat non-small cell lung cancer. It makes tumors more vulnerable to immune system attack. Pleural mesothelioma has many of the same characteristics as lung cancer. This is one reason researchers are hopeful about Opdivo for mesothelioma recurrence.  The primary treatment for mesothelioma is … Continue reading Opdivo for Mesothelioma Recurrence is Safe and Effective, Study Finds »

Rare But Dangerous Side Effects of Opdivo for Mesothelioma

side effects of Opdivo

Australian researchers are warning of some rare but deadly side effects of Opdivo (nivolumab) for pleural mesothelioma.  They have just published a case report of a mesothelioma patient on nivolumab, a drug often used to treat lung cancer. The patient developed swelling of the heart and other muscles. The swelling lasted for months, even after they stopped taking the drug.  The case report details the healthcare teams’ effort to manage these potentially lethal side effects of Opdivo. They caution that other immune checkpoint inhibitors might cause similar complications. How Opdivo Fights Mesothelioma The primary treatment for mesothelioma is chemotherapy with pemetrexed (Alimta). Eventually, most patients stop responding to chemotherapy. At that point, doctors may turn to an immunotherapy drug like … Continue reading Rare But Dangerous Side Effects of Opdivo for Mesothelioma »

PD-L1 Inhibitor Nivolumab Works Well in New Mesothelioma Study

PD-L1 inhibitor nivolumab

A study of the PD-L1 inhibitor nivolumab showed “safety and efficacy” in mesothelioma patients who failed with other treatments.  Nivolumab is a type of immunotherapy marketed under the brand name Opdivo. It is similar to pembrolizumab (Keytruda) in that it blocks the tumor-promoting protein PD-L1. Nivolumab is most often used for patients with non-small cell lung cancer.  A multicenter phase II Japanese study found the PD-L1 inhibitor nivolumab helped a group of pleural mesothelioma patients live longer. Just as importantly, the side effects of the drug were “manageable”.  Human Trial of PD-L1 Inhibitor Nivolumab Chemotherapy with pemetrexed (Alimta) and cisplatin is the standard first-line treatment for pleural mesothelioma. But many patients either do not respond to chemotherapy or they stop … Continue reading PD-L1 Inhibitor Nivolumab Works Well in New Mesothelioma Study »

Immunotherapy Prompts “Remarkable Response” in Sarcomatoid Pleural Mesothelioma

sarcomatoid pleural mesothelioma

Japanese doctors are reporting a remarkable response from the immunotherapy drug nivolumab in a patient with sarcomatoid pleural mesothelioma.  Sarcomatoid pleural mesothelioma is a very rare form of a rare cancer. It accounts for about 10 percent of cases of malignant mesothelioma.  This subtype is typically less responsive to standard treatments than the more common epithelioid variety. But researches at Kyushu Hospital in Fukuoka, Japan say nivolumab turned things around for their patient when the case looked hopeless.  How is Sarcomatoid Pleural Mesothelioma DIfferent? Malignant mesothelioma is a cancer of the linings around organs. Pleural mesothelioma grows on the pleural membrane that surrounds the lungs.  There are three cell subtypes of mesothelioma. The three subtypes respond differently to mesothelioma treatments. … Continue reading Immunotherapy Prompts “Remarkable Response” in Sarcomatoid Pleural Mesothelioma »

Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study

mesothelioma tumor response to nivolumab

An Indian woman in still alive two years after a mesothelioma diagnosis thanks to a remarkable mesothelioma tumor response to nivolumab. Nivolumab is sold under the brand name Opdivo. It is a type of immunotherapy. Nivolumab is sometimes used for lung cancer that progresses after chemotherapy. A hospital in Mumbai tried nivolumab on a pleural mesothelioma patient after several types of chemotherapy did not work. Doctors say the mesothelioma tumor response to nivolumab was so great that the patient no longer needed supplemental oxygen.  Opdivo in Mesothelioma Treatment Opdivo is not FDA-approved for mesothelioma treatment. Only Alimta (pemetrexed) holds that designation. But pleural mesothelioma grows quickly and is hard to treat. Even the gold standard therapies often do not work … Continue reading Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study »

New Mesothelioma Immunotherapy Trial Now Underway at Baylor

mesothelioma clinical trial results

Cancer researchers at Baylor College of Medicine have launched a new mesothelioma immunotherapy trial. The trial combines the cancer drug Opdivo (nivolumab) with injections of a modified virus called MTG201. Baylor scientists are hoping to recruit 12 pleural mesothelioma patients whose cancer has come back after chemotherapy.  The treatment combination appeared to work well in mice with mesothelioma. If it works as well in people, this new mesothelioma immunotherapy trial could change the outlook for many people with malignant mesothelioma.  How the New Mesothelioma Immunotherapy Trial Will Work Opdivo is the brand name for nivolumab. It blocks a protein called PD-1 in cancer cells. PD-1 is one of the ways that mesothelioma cells evade the immune system. Opdivo is often … Continue reading New Mesothelioma Immunotherapy Trial Now Underway at Baylor »